Kidz-Med introduces all-natural multivitamin
WESTON, Fla. Kidz-Med, a subsidiary of American Scientific Resources, on Thursday announced that they have introduced an all-natural children’s multivitamin to their health and safety product line on www.kidzmed.com.
Christopher Tirotta, chief executive officer of ASR stated, “Due to the overwhelming demand in the nutraceutical market, we strongly believe that the addition of this multivitamin—as well as other future consumables—will obtain profitability.”
Kidz-Med’s Children’s Chewable 100 percent All Natural Multi-Vitamin contains no sugar, no dyes, no artificial additives and no preservatives. The unique blend has 100 percent of the 13 essential Recommended Daily Allowances of vitamins and minerals. According to the company, the complete multi-vitamin will give a child, ages 2-12, the proper nutrition according to RDA guidelines to ensure optimum health, strength and development.
For a two-month supply, the product retails for a suggested $12.95.
Kidz-Med already distributes their flagship product, the Thermofocus 5-in-1 non-contact thermometer, in 6,000 nationwide Walgreens.
Teva’s Azilect slows Parkinson’s disease in trials
WASHINGTON Results from a Phase III clinical trial have shown that Teva Pharmaceutical’s Azilect 1-mg tablets can slow the progression of the disease, the drug maker announced.
Researchers gave 1,176 Parkinson’s disease patients daily 1- to 2-mg doses of Azilect for 18 months or a placebo for the first nine months and the drug for the second nine months.
Patients who took the 1-mg dose of Azilect showed significant improvement compared with patients in the placebo group.
The Food and Drug Administration approved Azilect in May 2006 as a monotherapy for early-stage ParkinsonOs disease and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease.
The drug, known generically as rasagiline mesylate, is available in 30 countries. Danish drug maker Lundbeck markets it in Europe, and both companies plan to co-promote it in the United Kingdom, Germany and France.
Taro to ask for extension on Sun Pharmaceuticals’ offer
TEL AVIV,, Israel Taro Pharmaceutical Industries has said it will appeal to Israel’s Supreme Court to contest a ruling in the Tel Aviv District Court regarding India-based Sun Pharmaceuticals’ offer to acquire the Israeli generic drug maker.
The District Court judge had called Taro’s demand for a tender offer from Sun disingenuous, considering Taro’s acceptance of the offer a year ago.
Taro plans to ask the Supreme Court to extend the deadline for Sun’s offer, which was Tuesday at 5 p.m.